期刊文献+

甲型H1N1流感肺炎危重病例的临床分析 被引量:5

Clinical analysis of critically ill patients with pneumonia of influenza A HIN1
原文传递
导出
摘要 目的分析甲型H1N1流感肺炎危重病例的临床特点及危重症的相关危险因素。方法采用回顾性研究方法分析承德市第三医院2009年9~12月收治的51例新型甲型H1N1流感肺炎患者的临床特点,并对重症病例和危重症病例进行比较分析。结果危重症患者均有呼吸困难,氧合指数为(188.4±68.5)mmHg,APACHEⅡ评分为12.5±4.5。其中10例(41.7%)出现咳痰带血,6例(25.0%)发展至急性呼吸窘迫综合征(ARDS)。危重症组在白细胞升高、淋巴细胞降低、血糖升高、痰培养阳性及应用奥司他韦(300mg/d)、美洛培南、丙种球蛋白、近期康复者血浆、机械通气、糖皮质激素的患者比例上较重症组高(P值均〈O.05);危重症组受损肺野数量、咽拭子转阴时间、住院时间上较重症组高(P值均〈O.05)。logistic回归分析结果显示:首发症状有咳痰、发病到应用奥司他韦时间〉48h、伴随基础疾病是易于发展至危重症的危险因素(OR值分别为3.181、19.596、7.437,P值均〈0.05)。结论首发症状有咳痰、发病到应用奥司他韦时间〉48h、伴随基础疾病的甲型H1N1流感肺炎患者易发展至危重症;危重症患者受损肺组织广泛且部分合并细菌感染,病毒转阴时间和住院时间长,部分患者进展至ARDS。 Objective To analyze the clinical features of critically ill patients with pneumonia of influenza A HIN1 and the risk factors associated with critically ill patients. Methods The clinical features of 51 patients with pneumonia of influenza A H1N1 hospitalized at Chengde Third Hospital from September to December of 2009 were retrospectively analyzed and the comparative analysis was performed on the clinical features of the severe and the critically ill patients. Results Critically ill patisents all had dyspnea, average oxygenation index was (188.4± 68.5) mm Hg and average APACHE 1I score was 12.5±4.5, and ten patients (41.7 % ) had bloody spumtum, six critically ill patients (25.0 a//00 ) progressed to acute repiratory distress syndrome (ARDS). The ratios of patients with increased leukocytosis, decreased lymphocytes,elevated blood sugar, positive sputum culture, and received osehamivir (300 mg/d), meropenem, gamma globulin, convalescen plasma, mechanical ventilation, glucocorticoid were higher in critical group than those in severe group (all P 〈 0.05). The number of damaged lung field, viral clearance time,and hospitalization time were higher in critical group than those in severe group (all P 〈 0.05). Logistic regression analysis showed that pneumonia of inflenza A H1N1 with expectoration as initial symptom, the onset to first dose of oseltamivir 〉48 hours,and presences of underlying disease was associated with higher fatal risks (OR was 3. 181,19. 596,7. 437 respectively, all P d0.05). Conclusions Pneumonia of inflenza A H1NI with expectoration as initial sympom, the onset to first dose of oseltamivir 〉48 hours,and presences of underlying disease is susceptible to critical illness. Damaged lung tissue of critically ill patients is wide and some are complicated with bacterial infection, viral clearance timeand hospital stay are longer,part of patients progress to ARDS.
出处 《国际呼吸杂志》 2013年第14期1046-1050,共5页 International Journal of Respiration
基金 承德市科学技术研究与发展计划项目(20122175)
关键词 甲型H1N1流感 肺炎 危重症 临床特征 危险因素 Influenza A ( H1N1) Pneumonia Critical illness Clinical features Risk factor
  • 相关文献

参考文献11

  • 1New influenza A (HIN1) virus: global epidemiologieal situation, June 2009. Wkly Epidemiol Rec, 2009, 84: 249- 257.
  • 2Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, Bautista E, Chotpitayasunondh T, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med, 2010, 362,1708-1719.
  • 3中华人民共和国卫生部.甲型H1N1流感诊疗方案(2009年第三版).[2009-11-25].http://www.moh.gov.cn/.
  • 4Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA, 2009,302 : 1872-1879.
  • 5ANZIC Influenza Investigators, Webb SA, Pettila V, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med, 2009,361 : 1925-1934.
  • 6段雪晶,李勇,宫恩聪,王珏,吕福东,张贺秋,孙琳,岳竹君,宋晨朝,张世杰,李宁,戴洁.重症甲型H1N1流感八例呼吸系统病理学特征分析[J].中华病理学杂志,2011,40(12):825-829. 被引量:4
  • 7Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med, 2009,361 : 1935-1944.
  • 8Centers for Disease Control and Prevention (CDC). Bacterial eoinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States, May-August 2009. MMWR Morb Mortal Wkly Rep, 2009,58 : 1071-1074.
  • 9Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S,et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med, 2009,361 : 680-689.
  • 10Dellinger RP, Levy MM, Carlet JM,et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med, 2008,36 : 296-327.

二级参考文献30

  • 1Centers for Disease Control and Prevention (CDC).Swine influenza A (H1N1) infection in two children--Southern California,March-April 2009.MMWR Morb Mortal Wkly Rep,2009,58(15):400-402.
  • 2Centers for Disease Control and Prevention (CDC).Update:swine influenza A (H1N1) infections--California and Texas,April 2009.MMWR Morb Mortal Wkly Rep,2009,58(16):435-437.
  • 3Centers for Disease Control and Prevention (CDC).Update:novel influenza A (H1N1) virus infection-Mexico,March-May,2009.MMWR Morb Mortal Wkly Rep,2009,58(21):585-589.
  • 4Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team,Dawood FS,Jain S,et al.Emergence of a novel swineorigin influenza A (H1 N1) virus in humans.N Engl J Med,2009,360 (25):2605-2615.
  • 5Zimmer SM,Burke DS.Historical perspective.Emergence of influenza A (H 1N 1) viruses.N Engl J Med,2009,361 (3):279-285.
  • 6Zarocostas J.World Health Organization declares A (H1N1)influenza pandemic.BMJ,2009,338:b2425.
  • 7[No authors listed] Outbreak news.Swine influenza.Wkly Epidemiol Rec,2009,84 (18):149.
  • 8Mauad T,Hajjar LA,Callegari GD,et al.Lung pathology in fatal novel human influenza A (H1 N1) infection.Am J Respir Crit Care Med,2010,181 (1):72-79.
  • 9Neumann G,Noda T,Kawaoka Y.Emergence and pandemic potential of swine-origin H1N1 influenza virus.Nature,2009,459(7249):931-939.
  • 10Perez-Padilla R,de la Rosa-Zamboni D,Ponce de Leon S,et al.Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.N Engl J Med,2009,361(7):680-689.

共引文献10

同被引文献85

  • 1von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors[J]. Nat Rev Drug Discov, 2007,6 (12) : 967-974.
  • 2Moscona A. Medical management of influenza infection [J]. Annu Rev Med, 2008, 59: 397-413.
  • 3Schulman JL, Palese P. Susceptibility of different strains of influenza a virus to the inhibitory effects of 2-deoxy-2, 3- dehydro-N-trifluoroacetylneuraminie acid ( FANA ) [ J ]. Virology, 1975,63(1) :98-104.
  • 4Tailor NR, von Itzsteln NM. Molecular modeling studies on hgand binding io siai;'iase from influenza virus and the mechanism of cataiysis [J]. J Med Chem, 1994, 37 (5) : 616- 624.
  • 5Moseona A. Neuraminidase inhibitors for influenza [J]. N Engl J Med, 2005, 353 (13): 1363-137.
  • 6N6hle U, Beau JM, Schauer R. Uptake, Metabolism and excretion of orally and intravenously administered, double- labeled N-gIycoloylneuraminic acid and single-labeled 2- deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat [J] i Eur J Bioehem, 1982, 126(3): 543-548.
  • 7von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication [J]. Nature, 1993, 363 (6428): 418-423.
  • 8Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active structural analysis of earbocyclie potent anti-influenza activity[J] site: design, synthesis, and sialic acid analogues with J Am Chem Soc, 1997, 119(4):681-690.
  • 9Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ 270201) : discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [J]. J Med Chem, 2000,43 (19) : 3482-3486.
  • 10Ikematsu H, Kawai N. Laninamivir octanoate: a new long- acting neuraminidase inhibitor for the treatment of influenza [J]. Expert Rev Anti Infect Ther, 2011, 9(10):851-857.

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部